S3 Table. Published studies of *BRCA1/2* mutations reported from Korean ovarian cancer patients

Characteristic	Lim et al. (2009) [1]	Choi et al. (2015) [2]	Eoh et al. (2017) [3]
Total No.	63	70	116[a)]
Overall prevalence of *BRCA1/2* mutations	15/63 (23.8)	18/70 (25.7)	37/116 (31.9)
Prevalence of *BRCA1/2* mutations with FHBOC	13/40 (32.5)	11/18 (61.1)	18/47 (38.2)
Prevalence of *BRCA1/2* mutations without FHBOC	2/23 (8.7)	7/52 (13.5)	16/65 (24.6)

Values are presented as number (%). FHBOC, family history of breast/ovarian cancer. [a)]FHBOC of four cases was unknown.

References

1. Lim MC, Kang S, Seo SS, Kong SY, Lee BY, Lee SK, et al. BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients. J Cancer Res Clin Oncol. 2009;135:1593-9.

2. Choi MC, Heo JH, Jang JH, Jung SG, Park H, Joo WD, et al. Germline mutations of BRCA1 and BRCA2 in Korean ovarian cancer patients: finding founder mutations. Int J Gynecol Cancer. 2015;25:1386-91.

3. Eoh KJ, Park HS, Park JS, Lee ST, Han J, Lee JY, et al. Comparison of clinical outcomes of BRCA1/2 pathologic mutation, variants of unknown significance, or wild type epithelial ovarian cancer patients. Cancer Res Treat. 2017;49:408-15.